Skip to main content

Table 3 Comparison of individual-level characteristics, between trial arms

From: The Lake Victoria island intervention study on worms and allergy-related diseases (LaVIISWA): study protocol for a randomised controlled trial

Characteristics1

Standard anthelminthic treatment (n = 1,159)

Intensive anthelminthic treatment (n = 1,157)

Socio-demographic characteristics

  

Age in years, median (IQR)

24 (8 to 33)

24 (7 to 32)

Sex, % male

56%

53%

Occupation type (adults only)

  

No personal income

11%

10%

Unskilled, no income

16%

22%

Some skill or capital required, low income

59%

46%

Education, skills or capital required, low to moderate income

5%

9%

Facility owner (such as a shop, boat, or restaurant)

8%

11%

Maternal tribe

  

Central

29%

36%

Western

16%

12%

Eastern

19%

23%

Northern

17%

14%

Non-Ugandan

18%

14%

Paternal tribe

  

Central

33%

40%

Western

15%

12%

Eastern

20%

21%

Northern

18%

14%

Non-Ugandan

13%

12%

Number of older siblings, mean (SD)

2.8 (2.8)

2.9 (3.1)

Number of younger siblings, mean (SD)

2.6 (2.7)

2.6 (2.7)

Any previous worm treatment in last 12 months

44%

39%

Treatment with albendazole in last 12 months

29%

27%

Treatment with praziquantel in last 12 months

20%

14%

Infections

  

Schistosoma mansoni (Kato-Katz)

56%

49%

Schistosoma mansoni (urine CCA)

72%

73%

Schistosoma mansoni intensity (Kato-Katz)

  

Uninfected

44%

51%

Low

22%

21%

Moderate

15%

13%

Heavy

18%

14%

Hookworm (Necator americanus; PCR)

23%

23%

Strongyloides stercoralis (PCR)

13%

13%

Trichuris trichiura (Kato-Katz)

12%

11%

Ascaris lumbricoides (Kato-Katz)

2%

1%

Mansonella perstans

3%

2%

Plasmodium falciparum

6%

7%

HIV (adults only)

17%

19%

  1. 1Missing values in standard and intensive arms respectively: age: 4, 1; sex: 6, 7; occupation: 8, 7; maternal tribe: 18, 17; paternal tribe: 15, 17; older siblings: 6, 7; younger siblings: 7, 9; any worm treatment: 17, 15; albendazole treatment: 28, 32; praziquantel treatment: 30, 31; Kato-Katz results: 172, 148; PCR results: 172, 150; urine results: 642, 757; M. perstans: 115, 102; P. falciparum: 107, 94; HIV: 65, 60. CCA, circulating cathodic antigen; IQR, interquartile range; PCR, polymerase chain reaction.